Currently, there are 127.10M common shares owned by the public and among those 124.66M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -7.73% and -28.20% over the past three months. BAH shares are trading -17.80% year to date (YTD), with the 12-month market performance down to -28.38% lower. It has a 12-month low price of $101.82 and touched a high of $190.59 over the same period. BAH has an average intraday trading volume of 2.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.25%, -16.37%, and -28.63% respectively.
Institutional ownership of Booz Allen Hamilton Holding Corp (NYSE: BAH) shares accounts for 95.96% of the company’s 127.10M shares outstanding.
It has a market capitalization of $13.40B and a beta (3y monthly) value of 0.59. The stock’s trailing 12-month PE ratio is 15.77, while the earnings-per-share (ttm) stands at $6.71. The company has a PEG of 1.24 and a Quick Ratio of 1.57 with the debt-to-equity ratio at 2.97. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.63% over the week and 3.90% over the month.
Earnings per share for the fiscal year are expected to increase by 15.34%, and 10.59% over the next financial year. EPS should grow at an annualized rate of 12.72% over the next five years, compared to 9.55% over the past 5-year period.
Cantor Fitzgerald coverage for the Booz Allen Hamilton Holding Corp (BAH) stock in a research note released on February 07, 2025 offered a Overweight rating with a price target of $160. Raymond James was of a view on February 03, 2025 that the stock is Outperform, while Barclays gave the stock Equal Weight rating on January 06, 2025, issuing a price target of $140. UBS on their part issued Neutral rating on December 02, 2024.
